Trial Profile
A prospective multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib) in Combination with Obinutuzumab (GA 101) in Patients with Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms ALTERNATIVE
- 04 Dec 2018 Results assessing efficacy of Obinutuzumab and Ibrutinib in follicular lymphoma patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 13 Aug 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Apr 2022.
- 24 Jul 2017 Status changed from recruiting to active, no longer recruiting.